Telix ADRs rise after FDA approves Pixclara brain imaging
Telix Pharmaceuticals Limited ADRs gained after the FDA approved its new drug application for Pixclara, used in brain cancer imaging; ADRs rose 7.9% to $12.18 in premarket.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.